How to buy DiaMedica Therapeutics stock (DMAC)

DiaMedica Therapeutics is a biotechnology business based in the US. DiaMedica Therapeutics shares (DMAC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.41 – a decrease of 15.6% over the previous week. DiaMedica Therapeutics employs 18 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy DiaMedica Therapeutics stock

Buy DiaMedica Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

DiaMedica Therapeutics stock price (NASDAQ: DMAC)

Use our graph to track the performance of DMAC stocks over time.

DiaMedica Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$5.41
52-week range	$2.14 - $6.41
50-day moving average more info button	$4.72
200-day moving average more info button	$3.63
Wall St. target price	$7.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.56

Is it a good time to buy DiaMedica Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DiaMedica Therapeutics price performance over time

Historical closes compared with the close of $5.34 from 2024-12-26

1 week (2024-12-20)	-16.69%
1 month (2024-11-27)	2.50%
3 months (2024-09-27)	27.75%
6 months (2024-06-28)	81.02%

1 year (2023-12-28)	83.51%
2 years (2022-12-28)	245.63%
3 years (2021-12-28)	54.78%
5 years (2019-12-27)	8.54%

DiaMedica Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-23.54%
Return on equity TTM	-35.18%
Profit margin	0%
Book value	$1.35
Market Capitalization more info button	$224.9 million

TTM: trailing 12 months

DiaMedica Therapeutics share dividends

We're not expecting DiaMedica Therapeutics to pay a dividend over the next 12 months.

Have DiaMedica Therapeutics's shares ever split?

DiaMedica Therapeutics's shares were split on a 1:20 basis on 14 November 2018 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DiaMedica Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for DiaMedica Therapeutics shares which in turn could have impacted DiaMedica Therapeutics's share price.

DiaMedica Therapeutics share price volatility

Over the last 12 months, DiaMedica Therapeutics's shares have ranged in value from as little as $2.14 up to $6.41. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DiaMedica Therapeutics's is 1.456. This would suggest that DiaMedica Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

DiaMedica Therapeutics overview

DiaMedica Therapeutics Inc. , a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc.

Frequently asked questions

null
What percentage of DiaMedica Therapeutics is owned by insiders or institutions?
Currently 26.225% of DiaMedica Therapeutics shares are held by insiders and 31.608% by institutions. How many people work for DiaMedica Therapeutics?
Latest data suggests 18 work at DiaMedica Therapeutics. When does the fiscal year end for DiaMedica Therapeutics?
DiaMedica Therapeutics's fiscal year ends in December. Where is DiaMedica Therapeutics based?
DiaMedica Therapeutics's address is: 301 Carlson Parkway, Minneapolis, MN, United States, 55305 What is DiaMedica Therapeutics's ISIN number?
DiaMedica Therapeutics's international securities identification number is: CA25253X2077 What is DiaMedica Therapeutics's CUSIP number?
DiaMedica Therapeutics's Committee on Uniform Securities Identification Procedures number is: 25253X207